MedTrace Logo

Safety and Efficacy Study of CUBICIN (Daptomycin) Under Conditions of Actual Use

NCT01219114 · Status: WITHDRAWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2011-09-28

No results posted yet for this study

Summary

The purpose of this study is to monitor the safety and efficacy of CUBICIN under conditions of actual use in patients who are diagnosed with complicated Skin and Skin Structure infection (cSSI) or Staphylococcus aureus bacteria including right-sided endocarditis and are prescribed CUBICIN by their physician.

Conditions

  • Complicated Skin and Skin Structure Infections and Bacteremia Including Right-sided Endocarditis

Sponsors & Collaborators

Principal Investigators

  • Milagros Tan, MD · AstraZeneca Philippines

  • Emmanuel Arca, MD · AstraZeneca Philippines

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2013-10-31
Completion
2013-11-30

Countries

  • Philippines

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01219114 on ClinicalTrials.gov